QUOTE AND NEWS
FiercePharma  May 24  Comment 
A Vivus shareholder who wants to stack the drugmaker's board with a more aggressive slate of directors has brought in one of the champions of this kind of shareholder brawl. Alex Denner, who gained his experience in proxy fights as the head of...
StreetInsider.com  May 22  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/VIVUS%2C+Inc.+%28VVUS%29+to+Make+Several+Scientific+Presentations+in+May/8360711.html for the full story.
StreetInsider.com  May 20  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/QVT+Financial+Purchase+%2420M+of+Convertible+Debt+Issued+by+VIVUS+%28VVUS%29/8355998.html for the full story.
StreetInsider.com  May 16  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/VIVUS+%28VVUS%29+Prices+%24220M+Convertible+Debt+Offering/8345549.html for the full story.
StreetInsider.com  May 15  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/VIVUS+%28VVUS%29+Launches+%24200M+Convertible+Notes+Offering/8339301.html for the full story.
Benzinga  May 14  Comment 
Vivus (NASDAQ: VVUS) is currently up nearly 2 percent despite being downgraded from Buy to Neutral at Lazard Capital Markets. Traders in Vivus are continuing to responding to news from Monday the company's CEO said the company is in...
StreetInsider.com  May 13  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/VIVUS+%28VVUS%29+CEO+Wilson+Issues+Shareholder+Letter%3B+Plans+on+Broader+Qsiva+Expansion/8329644.html for the full story.
FiercePharma  May 9  Comment 
Vivus' announcement that the company is looking to partner with Big Pharma for marketing help to get its new weight-loss drug, Qsymia, off the ground apparently encouraged investors. Shares rose 9.7% to $13.21, the biggest one-day increase since...





 




References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki